1. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (May 2022) Authors: Blach, Sarah; Terrault, Norah A; Tacke, Frank; Gamkrelidze, Ivane; Craxi, Antonio; Tanaka, Junko; Waked, Imam; Dore, Gregory J; Abbas, Zaigham; Abdallah, Ayat R; Abdulla, Maheeba; Aghemo, Alessio; Aho, Inka; Akarca, Ulus S; Alalwan, Abduljaleel M; Alanko Blomé, Marianne; Al-Busafi, Said A; Aleman... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 5(2022) Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (March 2017) Authors: Blach, Sarah; Zeuzem, Stefan; Manns, Michael; Altraif, Ibrahim; Duberg, Ann-Sofi; Muljono, David H; Waked, Imam; Alavian, Seyed M; Lee, Mei-Hsuan; Negro, Francesco; Abaalkhail, Faisal; Abdou, Ahmed; Abdulla, Maheeba; Rached, Antoine Abou; Aho, Inka; Akarca, Ulus; Al Ghazzawi, Imad; Al Kaabi, Saad... Journal: Lancet gastroenterology and hepatology Issue: Volume 2:Number 3(2017) Page Start: 161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Issue 10003 (17th October 2015) Authors: Roth, David; Nelson, David R; Bruchfeld, Annette; Liapakis, AnnMarie; Silva, Marcelo; Monsour, Howard; Martin, Paul; Pol, Stanislas; Londoño, Maria-Carlota; Hassanein, Tarek; Zamor, Philippe J; Zuckerman, Eli; Wan, Shuyan; Jackson, Beth; Nguyen, Bach-Yen; Robertson, Michael; Barr, Eliav; Wahl, Ja... Journal: Lancet Issue: Volume 386:Issue 10003(2015) Page Start: 1537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. HCV Genotype-1 Subtypes and Resistance-Associated Substitutions in Drug-Naive and in Direct-Acting Antiviral Treatment Failure Patients. Issue 5 (July 2017) Authors: Gozlan, Yael; Ben-Ari, Ziv; Moscona, Roy; Shirazi, Rachel; Rakovsky, Aviya; Kabat, Arij; Veizman, Ella; Berdichevski, Tania; Weiss, Peretz; Cohen-Ezra, Oranit; Lurie, Yoav; Gafanovich, Inna; Braun, Marius; Cohen-Naftaly, Michal; Shlomai, Amir; Shibolet, Oren; Zigmond, Ehud; Zuckerman, Eli; Carmie... Journal: Antiviral therapy Issue: Volume 22:Issue 5(2017) Page Start: 431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. High Frequency of Multiclass HCV Resistance-Associated Mutations in Patients Failing Direct-Acting Antivirals: Real-Life Data. Issue 3 (April 2019) Authors: Gozlan, Yael; Bucris, Efrat; Shirazi, Rachel; Rakovsky, Avia; Ben-Ari, Ziv; Davidov, Yana; Veizman, Ella; Saadi, Tarek; Braun, Marius; Cohen-Naftaly, Michal; Shlomai, Amir; Shibolet, Oren; Zigmond, Ehud; Katchman, Helena; Menachem, Yoram; Safadi, Rifaat; Galun, Eitan; Zuckerman, Eli; Nimer, Assy;... Journal: Antiviral therapy Issue: Volume 24:Issue 3(2019) Page Start: 221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10215 (14th December 2019) Authors: Younossi, Zobair M; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N; Sheridan, David; Sheikh, Muhammad Y; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F; Kowdley, Kris V;... Journal: Lancet Issue: Volume 394:Issue 10215(2019) Page Start: 2184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Issue 10215 (14th December 2019) Authors: Younossi, Zobair M; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M; Goodman, Zachary; Bedossa, Pierre; Geier, Andreas; Beckebaum, Susanne; Newsome, Philip N; Sheridan, David; Sheikh, Muhammad Y; Trotter, James; Knapple, Whitfield; Lawitz, Eric; Abdelmalek, Manal F; Kowdley, Kris V;... Journal: Lancet Issue: Volume 394:Issue 10215(2019) Page Start: 2184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗